We are live on ! Find out more
NVO

Novo Nordisk

580 hedge funds and large institutions have $9.18B invested in Novo Nordisk in 2019 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 171 increasing their positions, 204 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more call options, than puts

Call options by funds: $58.1M | Put options by funds: $23.1M

88% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 41

15% more capital invested

Capital invested by funds: $7.99B → $9.18B (+$1.19B)

5% more funds holding

Funds holding: 550580 (+30)

0.2% more ownership

Funds ownership: 18.15%18.35% (+0.2%)

16% less repeat investments, than reductions

Existing positions increased: 171 | Existing positions reduced: 204

17% less funds holding in top 10

Funds holding in top 10: 1210 (-2)

Holders
580
Holders Change
+30
Holders Change %
+5.45%
% of All Funds
12.55%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.22%
New
77
Increased
171
Reduced
204
Closed
41
Calls
$58.1M
Puts
$23.1M
Net Calls
+$35M
Net Calls Change
-$10.8M

NVO Hedge Fund Activity: Q1 2019 in Review

580 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2019, worth a combined $9.18B — up 15% from $7.99B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new NVO positions and 41 closed out — a net gain of 36 holders — while 171 added to existing stakes and 204 trimmed.

The largest buyer was Amundi Asset Management US, opening a new position worth an estimated $46.1M. The largest seller was Alta Capital Management, cutting an estimated $41.5M.

  • 580 institutional investors held Novo Nordisk (NVO) as of Q1 2019, up from 550 in Q4 2018.
  • Funds reported $9.18B of Novo Nordisk stock for Q1 2019, up 15% quarter-over-quarter.
  • 77 funds opened new Novo Nordisk positions in Q1 2019 and 41 closed out, a net change of +36 holders.
  • The largest Novo Nordisk buyer in Q1 2019 was Amundi Asset Management US, an estimated $46.1M added.
  • The largest Novo Nordisk seller in Q1 2019 was Alta Capital Management, an estimated $41.5M sold.

Based on aggregated 13F filings for Q1 2019.